Emodin delays rheumatoid arthritis progression by inhibiting the ROS/TXNIP/NLRP3 signaling pathway
Related Experiment Video
Updated: May 21, 2025

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
Linlan Zhou1, Jun Liu2, Kang Yang3
1Department of Combination of Chinese and Western Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China; Chongqing Key Laboratory of Traditional Chinese Medicine for Prevention and Cure of Metabolic Diseases, Chongqing 400016, China.
Abstract:
Rheumatoid arthritis (RA) is a chronic autoimmune disorder affecting small joints of the hands, feet, and ankles, causing synovitis, pannus formation, and vasculitis. RA can lead to joint destruction and multi-system complications. Emodin (EMO), the primary active component of rhubarb, has significant anti-inflammatory properties and therapeutic potential in alleviating RA symptoms. This study focused on this therapeutic efficacy and underlying mechanisms. Collagen-induced arthritis (CIA) mouse models and lipopolysaccharide (LPS)-stimulated RAW264.7 cells were used to investigate the effects of EMO on pathological markers, inflammatory factors, and oxidative stress through histopathological analysis, western blotting, micro-computed tomography (CT), and immunohistochemistry (IHC). Proteomics, molecular docking, and molecular dynamics (MD) simulations were used to identify key targets and to elucidate the mechanisms of action underlying the therapeutic efficacy of EMO. EMO alleviated joint swelling, reduced arthritis scores, and mitigated bone damage in mice with CIA. EMO significantly decreased inflammatory factor levels and attenuated oxidative stress, as shown through reduced reactive oxygen species (ROS) and malondialdehyde (MDA) levels and increased superoxide dismutase (SOD) activity. EMO inhibited inflammasome activation, as indicated by reduced NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3), caspase-1, apoptosis-associated speck-like protein containing a CARD (ASC), interleukin (IL)-1β, and IL-18 expression. The analyses showed that the anti-inflammatory effects of EMO are mediated through ROS/TXNIP/NLRP3 signaling pathway inhibition. Collectively, EMO downregulated inflammatory responses and oxidative stress, inhibited inflammasome activation, and alleviated RA symptoms through ROS/TXNIP/NLRP3 signaling pathway suppression. These findings highlight its potential for RA treatment and provide insights into its mechanisms and clinical applications.
More Related Videos
11:34A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
Published on: April 11, 2025
11:03A Cryo-pulverization Protocol for Processing Mouse Paws to Evaluate Molecular Pathways of Tissue Inflammation in a Collagen Induced Arthritis Model
Published on: October 30, 2019
Related Concept Videos
The JAK-STAT Signaling Pathway
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Inflammatory Response
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System